Doxorubicin-loaded cyclic peptide nanotube bundles overcome chemoresistance in breast cancer cells

Journal of Biomedical Nanotechnology

Volumn 10, Issue 3, 2014, Pages 445-454

  Wang, Yongzhong ^a   Yi, Sijia ^a   Sun, Leming ^a   Huang, Yujian ^a   Lenaghan, Scott C ^a   Zhang, Mingjun ^a  

^a University of Tennessee   (United States)

Author keywords

Breast Cancer; Cyclic Peptide; Doxorubicin; Multidrug Resistance; Nanotube

Indexed keywords

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MCF-7 CELLS; NANOCONJUGATES; NANOTUBES, PEPTIDE; POLYETHYLENE GLYCOLS; POLYMERIZATION; TISSUE DISTRIBUTION;

EID: 84893793731     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1724     Document Type: Article

References (46)

1. S. Scanlon and A. Aggeli, Self-assembling peptide nanotubes. Nano Today 3, 22 (2008).
2. A. Petrov and G. F. Audette, Peptide and protein-based nanotubes for nanobiotechnology, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4, 575 (2012).
3. S. K. Smart, A. I. Cassady, G. Q. Lu, and D. J. Martin, The biocompatibility of carbon nanotubes. Carbon 44, 1034 (2006).
4. K. L. Aillon, Y. M. Xie, N. El-Gendy, C. J. Berkland, and M. L. Forrest, Effects of nanomaterial physicochemical properties on In vivo toxicity. Adv. Drug Del. Rev. 61, 457 (2009).
5. X. M. Li, Y. B. Fan, and F. Watari, Current investigations into carbon nanotubes for biomedical application. Biomed. Mater. 5, 022001 (2010).
6. X. M. Li, H. Gao, M. Uo, Y. Sato, T. Akasaka, Q. L. Feng, F. Z. Cui, X. H. Liu, and F. Watari, Effect of carbon nanotubes on cellular functions in vitro. J. Biomed. Mater. Res. A 91A, 132 (2009).
7. D. G. Fatouros, K. Power, O. Kadir, I. Dekany, S. N. Yannopoulos, N. Bouropoulos, A. Bakandritsos, M. D. Antonijevic, G. D. Zouganelis, and M. Roldo, Stabilisation of SWNTs by alkyl-sulfate chitosan derivatives of different molecular weight: Towards the preparation of hybrids with anticoagulant properties. Nanoscale 3, 1218 (2011).
8. R. J. Brea, C. Reiriz, and J. R. Granja, Towards functional bionanomaterials based on self-assembling cyclic peptide nanotubes. Chem. Soc. Rev. 39, 1448 (2010).
9. M. R. Ghadiri, J. R. Granja, R. A. Milligan, D. E. McRee, and N. Khazanovich, Self-assembling organic nanotubes based on a cyclic peptide architecture. Nature 366, 324 (1993).
10. M. Amorin, L. Castedo, and J. R. Granja, New cyclic peptide assemblies with hydrophobic cavities: The structural and thermodynamic basis of a new class of peptide nanotubes. J. Am. Chem. Soc. 125, 2844 (2003).
11. T. D. Clark, L. K. Buehler, and M. R. Ghadiri, Self-assembling cyclic β3-peptide nanotubes as artificial transmembrane ion channels. J. Am. Chem. Soc. 120, 651 (1998).
12. D. Gauthier, P. Baillargeon, M. Drouin and Y. L. Dory, Self-assembly of cyclic peptides into nanotubes and then into highly anisotropic crystalline materials. Angew. Chem. 113, 4771 (2001).
13. J. D. Hartgerink, J. R. Granja, R. A. Milligan, and M. R. Ghadiri, Self-assembling peptide nanotubes. J. Am. Chem. Soc. 118, 43 (1996).
14. W. S. Horne, C. D. Stout, and M. R. Ghadiri, A heterocyclic peptide nanotube. J. Am. Chem. Soc. 125, 9372 (2003).
15. R. M. Ghadiri, Cyclic peptide tube, U. S. Patent 6613875, September (2003).
16. J. R. Granja and M. R. Ghadiri, Channel-mediated transport of glucose across lipid bilayers. J. Am. Chem. Soc. 116, 10785 (1994).
17. J. Sanchez-Quesada, H. Sun Kim, and M. R. Ghadiri, A synthetic pore-mediated transmembrane transport of glutamic acid. Angew. Chem. Int. Ed. Engl. 40, 2503 (2001).
18. N. Khazanovich, J. R. Granja, D. E. McRee, R. A. Milligan and M. R. Ghadiri, Nanoscale tubular ensembles with specified internal diameters. Design of a self-assembled nanotube with a 13-.ANG. pore. J. Am. Chem. Soc. 116, 6011 (1994).
19. J. Sanchez-Quesada, M. R. Ghadiri, H. Bayley, and O. Braha, Cyclic peptides as molecular adapters for a pore-forming protein. J. Am. Chem. Soc. 122, 11757 (2000).
20. K. Motesharei and M. R. Ghadiri, Diffusion-limited size-selective ion sensing based on SAM-supported peptide nanotubes. J. Am. Chem. Soc. 119, 11306 (1997).
21. R. J. Brea, M. E. Vazquez, M. Mosquera, L. Castedo, and J. R. Granja, Controlling multiple fluorescent signal output in cyclic peptide-based supramolecular systems. J. Am. Chem. Soc. 129, 1653 (2007).
22. R. J. Brea, L. Castedo, J. R. Granja, M. Á. Herranz, L. Sánchez, N. Martín, W. Seitz, and D. M. Guldi, Electron transfer in Me-blocked heterodimeric α,γ-peptide nanotubular donor-acceptor hybrids. Proc. Natl. Acad. Sci. U.S.A. 104, 5291 (2007).
23. N. Ashkenasy, W. S. Horne, and M. R. Ghadiri, Design of selfassembling peptide nanotubes with delocalized electronic states. Small 2, 99 (2006).
24. F. Fujimura and S. Kimura, Columnar assembly formation and metal binding of cyclic tri-beta-peptides having terpyridine ligands. Org. Lett. 9, 793 (2007).
25. C. Reiriz, R. J. Brea, R. Arranz, J. L. Carrascosa, A. Garibotti, B. Manning, J. M. Valpuesta, R. Eritja, L. Castedo, and J. R. Granja, Alpha, gamma-peptide nanotube templating of one-dimensional parallel fullerene arrangements. J. Am. Chem. Soc. 131, 11335 (2009).
26. M. Mizrahi, A. Zakrassov, J. Lerner-Yardeni, and N. Ashkenasy, Charge transport in vertically aligned, self-assembled peptide nanotube junctions. Nanoscale 4, 518 (2012).
27. S. Fernandez-Lopez, H. S. Kim, E. C. Choi, M. Delgado, J. R. Granja, A. Khasanov, K. Kraehenbuehl, G. Long, D. A. Weinberger, K. M. Wilcoxen, and M. R. Ghadiri, Antibacterial agents based on the cyclic D, L-alpha-peptide architecture. Nature 412, 452 (2001).
28. J. T. Fletcher, J. A. Finlay, M. E. Callow, J. A. Callow, and M. R. Ghadiri, A combinatorial approach to the discovery of biocidal six-residue cyclic D, L-alpha-peptides against the bacteria methicillin-resistant Staphylococcus aureus (MRSA) and E. coli and the biofouling algae Ulva linza and Navicula perminuta. Chemistry 13, 4008 (2007).
29. W. S. Horne, C. M. Wiethoff, C. Cui, K. M. Wilcoxen, M. Amorin, M. R. Ghadiri, and G. R. Nemerow, Antiviral cyclic D, L-alphapeptides: Targeting a general biochemical pathway in virus infections. Bioorg. Med. Chem. 13, 5145 (2005).
30. W. H. Hsieh, S. F. Chang, H. M. Chen, J. H. Chen, and J. Liaw, Oral gene delivery with cyclo-(D-Trp-Tyr) peptide nanotubes. Mol. Pharm. 9, 1231 (2012).
31. G. E. Sims and T. J. Snape, A method for the estimation of polyethylene glycol in plasma protein fractions. Anal. Biochem. 107, 60 (1980).
32. E. Simone, T. Dziubla, V. Shuvaev, and V. R. Muzykantov, Synthesis and characterization of polymer nanocarriers for the targeted delivery of therapeutic enzymes. Methods Mol. Biol. 610, 145 (2010).
33. Y. Wang, L. Chen, Y. Ding, and W. Yan, Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro. Int. J. Pharm. 422, 409 (2012).
34. Y. Wang, J. Hao, Y. Li, Z. Zhang, X. Sha, L. Han, and X. Fang, Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3 tumors. Biomaterials 33, 4741 (2012).
35. Y. Wang, L. Sun, S. Yi, Y. Huang, S. C. Lenaghan, and M. Zhang, Naturally occurring nanoparticles from arthrobotrys oligospora as a potential immunostimulatory and antitumor agent. Adv. Funct. Mater. 23, 2175 (2013).
36. D. A. Evseenko, J. W. Paxton, and J. A. Keelan, ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R1357 (2006).
37. S. A. Morgan, J. V. Watson, P. R. Twentyman, and P. J. Smith, Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer. Br. J. Cancer 60, 282 (1989).
38. C. Riganti, C. Voena, J. Kopecka, P. A. Corsetto, G. Montorfano, E. Enrico, C. Costamagna, A. M. Rizzo, D. Ghigo, and A. Bosia, Liposome- encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol. Pharm. 8, 683 (2011).
39. Y. Tian, L. Bromberg, S. N. Lin, T. A. Hatton, and K. C. Tam, Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers. J. Control. Release 121, 137 (2007).
40. H. Wu, W. Fang, J. Yuan, H. Peng, X. Zhang, Y. Wang, and Y. Xiao, Site-directed mutagenesis and sulfhydryl PEGylation of lysostaphin. Chin. J. Biotechnol. 27, 1623 (2011).
41. V. Dartois, J. Sanchez-Quesada, E. Cabezas, E. Chi, C. Dubbelde, C. Dunn, J. Granja, C. Gritzen, D. Weinberger, M. R. Ghadiri, and T. R. Parr, Jr, Systemic antibacterial activity of novel synthetic cyclic peptides. Antimicrob. Agents Chemother. 49, 3302 (2005).
42. A. V. Kabanov, E. V. Batrakova, and V. Y. Alakhov, Pluronic block copolymers for overcoming drug resistance in cancer. Adv. Drug Deliv. Rev. 54, 759 (2002).
43. V. Alakhov, E. Klinski, S. Li, G. Pietrzynski, A. Venne, E. Batrakova, T. Bronitch, and A. Kabanov, Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf. B 16, 113 (1999).
44. T.-G. Iversen, T. Skotland, and K. Sandvig, Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today 6, 176 (2011).
45. J. You, F. Q. Hu, Y. Z. Du, and H. Yuan, Improved cytotoxicity of doxorubicin by enhancing its nuclear delivery mediated via nanosized micelles. Nanotechnology 19, 255103 (2008).
46. J. P. Gillet and M. M. Gottesman, Mechanisms of multidrug resistance in cancer. Methods Mol. Biol. 596, 47 (2010).